JP2014515367A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515367A5
JP2014515367A5 JP2014511908A JP2014511908A JP2014515367A5 JP 2014515367 A5 JP2014515367 A5 JP 2014515367A5 JP 2014511908 A JP2014511908 A JP 2014511908A JP 2014511908 A JP2014511908 A JP 2014511908A JP 2014515367 A5 JP2014515367 A5 JP 2014515367A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
dengue virus
inactivated dengue
inactivated
bulk preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014511908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515367A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/059879 external-priority patent/WO2012160199A1/en
Publication of JP2014515367A publication Critical patent/JP2014515367A/ja
Publication of JP2014515367A5 publication Critical patent/JP2014515367A5/ja
Pending legal-status Critical Current

Links

JP2014511908A 2011-05-26 2012-05-25 不活性化デング熱ウイルスワクチン Pending JP2014515367A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161490205P 2011-05-26 2011-05-26
US61/490,205 2011-05-26
US201161570966P 2011-12-15 2011-12-15
US61/570,966 2011-12-15
PCT/EP2012/059879 WO2012160199A1 (en) 2011-05-26 2012-05-25 Inactivated dengue virus vaccine

Publications (2)

Publication Number Publication Date
JP2014515367A JP2014515367A (ja) 2014-06-30
JP2014515367A5 true JP2014515367A5 (https=) 2015-06-11

Family

ID=46148894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511908A Pending JP2014515367A (ja) 2011-05-26 2012-05-25 不活性化デング熱ウイルスワクチン

Country Status (16)

Country Link
US (1) US20140112953A1 (https=)
EP (1) EP2714076A1 (https=)
JP (1) JP2014515367A (https=)
KR (1) KR20140033171A (https=)
CN (2) CN107050445A (https=)
AU (2) AU2012260807B2 (https=)
BR (1) BR112013030236A2 (https=)
CA (1) CA2837145A1 (https=)
CO (1) CO6811814A2 (https=)
EA (1) EA201391515A1 (https=)
IL (1) IL229307A0 (https=)
MX (1) MX349119B (https=)
PE (1) PE20140646A1 (https=)
PH (1) PH12013502442A1 (https=)
SG (1) SG194950A1 (https=)
WO (1) WO2012160199A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6781508B2 (ja) 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
WO2016145149A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
CN107921063A (zh) 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
CN108291205A (zh) 2015-09-26 2018-07-17 普莱瓦克斯免疫肿瘤学公司 用于产生树突细胞的组合物和方法
GB201522068D0 (en) 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
WO2017210215A1 (en) * 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー,インク. 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
CN107140625A (zh) * 2017-06-14 2017-09-08 中国海洋大学 一种利用植物油制备石墨烯薄膜的方法
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
MX2020004543A (es) 2017-11-03 2020-09-18 Takeda Vaccines Inc Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CN116983398A (zh) 2017-11-30 2023-11-03 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物以及其使用方法
WO2019112921A1 (en) 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
KR20220141280A (ko) * 2019-12-11 2022-10-19 엔이1 인코퍼레이티드 암 면역요법을 위한 개인맞춤형 종양 백신 및 이의 용도
EP4110381A1 (en) * 2020-02-27 2023-01-04 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
CN112546213A (zh) * 2020-12-31 2021-03-26 中国医学科学院医学生物学研究所 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用
CN115531529A (zh) * 2022-09-16 2022-12-30 大连理工大学 一种冻干保护剂在含铝佐剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254873B1 (en) * 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
KR20030055275A (ko) * 2000-10-02 2003-07-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 분할 외피 바이러스 제조물
RU2358763C2 (ru) * 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
US20090104226A1 (en) * 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
CN101360821A (zh) * 2005-11-21 2009-02-04 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
EP2940129B1 (en) * 2007-04-06 2020-05-06 Takeda Vaccines, Inc. Methods and compositions for live attenuated viruses
JP5676452B2 (ja) * 2008-09-29 2015-02-25 カディラ ファーマシューティカルズ リミテッド ワクチンアジュバント
AR075437A1 (es) * 2009-02-17 2011-03-30 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento
US9005633B2 (en) * 2009-07-17 2015-04-14 The United States Of America As Represented By The Secretary Of The Navy. Psoralen-inactivated viral vaccine and method of preparation
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine

Similar Documents

Publication Publication Date Title
JP2014515367A5 (https=)
US11406698B2 (en) Vaccine compositions
TWI812650B (zh) 包含特別是減毒活重組黃病毒的穩定疫苗組成物以及製備其的製程
US9844588B2 (en) Inactivated chikungunya viruses (CHIKV) comprising an E1-K211E mutation
US11883480B2 (en) Formulations of dengue virus vaccine compositions
US10143741B2 (en) Immunization compositions and methods
CN103619349A (zh) 灭活登革热病毒疫苗
US10233429B2 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AU2012260807A1 (en) Inactivated Dengue virus vaccine
WO2017156511A8 (en) Live attenuated zika virus vaccine
US20190255125A1 (en) Vaccine compositions comprising an attenuated mutant zika virus
EP3481848B1 (en) Genomic sequences encoding for an attenuated mutant zika virus
US20220347286A1 (en) Inactivated vaccine for chikungunya virus
WO2017109698A1 (en) Immunogenic formulation
BR112018000862B1 (pt) Composição de vacina estável, método para produção de antígeno de vírus da zika recombinante e método para preparação de antígeno de virião (vírus) inteiro inativado da zika para formulação de vacina de vírus da zika